Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Tesch

Showing results (61-70 of 171) with videos related to

Pageof 18
Sort By:
Breast Cancer Research and Treatment|June 14, 2011
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40)Gunter von Minckwitz, Silvia Darb-Esfahani, Sibylle Loibl, et al.
BMC Cancer|July 9, 2016
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trialJulia Jueckstock, Brigitte Rack, Thomas W P Friedl, et al.
Breast Cancer Research : BCR|February 9, 2013
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancerCarsten Denkert, Jens Huober, Sibylle Loibl, et al.
Clinical Breast Cancer|June 19, 2023
Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer PatientsMarie Tzschaschel, Thomas W P Friedl, Fabienne Schochter, et al.
Annals of Surgical Oncology|April 18, 2014
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)Bernd Gerber, Gunter von Minckwitz, Holger Eidtmann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trialsGustavo Werutsky, Michael Untch, Claus Hanusch, et al.
Breast Cancer Research : BCR|September 24, 2024
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancerBruno Valentin Sinn, Katharina Sychra, Michael Untch, et al.
The Lancet. Oncology|January 20, 2012
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trialMichael Untch, Sibylle Loibl, Joachim Bischoff, et al.
Geburtshilfe Und Frauenheilkunde|March 19, 2019
Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical PracticeWolfgang Janni, Andreas Schneeweiss, Volkmar Müller, et al.
Geburtshilfe Und Frauenheilkunde|March 19, 2019
Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast CancerAndreas D Hartkopf, Volkmar Müller, Achim Wöckel, et al.
Pageof 18

Showing results (61-70 of 171) with videos related to

Sort By:
Pageof 18
Breast Cancer Research and Treatment|June 14, 2011
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40)Gunter von Minckwitz, Silvia Darb-Esfahani, Sibylle Loibl, et al.
BMC Cancer|July 9, 2016
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trialJulia Jueckstock, Brigitte Rack, Thomas W P Friedl, et al.
Breast Cancer Research : BCR|February 9, 2013
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancerCarsten Denkert, Jens Huober, Sibylle Loibl, et al.
Clinical Breast Cancer|June 19, 2023
Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer PatientsMarie Tzschaschel, Thomas W P Friedl, Fabienne Schochter, et al.
Annals of Surgical Oncology|April 18, 2014
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)Bernd Gerber, Gunter von Minckwitz, Holger Eidtmann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trialsGustavo Werutsky, Michael Untch, Claus Hanusch, et al.
Breast Cancer Research : BCR|September 24, 2024
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancerBruno Valentin Sinn, Katharina Sychra, Michael Untch, et al.
The Lancet. Oncology|January 20, 2012
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trialMichael Untch, Sibylle Loibl, Joachim Bischoff, et al.
Geburtshilfe Und Frauenheilkunde|March 19, 2019
Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical PracticeWolfgang Janni, Andreas Schneeweiss, Volkmar Müller, et al.
Geburtshilfe Und Frauenheilkunde|March 19, 2019
Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast CancerAndreas D Hartkopf, Volkmar Müller, Achim Wöckel, et al.
Pageof 18